MedTrace Logo

Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis

NCT03025269 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-03-11

No results posted yet for this study

Summary

This is a Phase IV, prospective, open-label, single-center, observational, longitudinal, single blinded study. The investigators will examine the effects of Ocrelizumab on cognitive, patient reported outcomes (PROs), quality of life (QoL), multiple sclerosis functional composite (MSFC), working status and magnetic resonance imaging (MRI) outcomes across 12 and 24 months.

Conditions

Interventions

DRUG

Ocrelizumab

This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments

Sponsors & Collaborators

  • University at Buffalo

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2022-01-08
Completion
2022-01-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03025269 on ClinicalTrials.gov